AstraZeneca Sees Positive Results for Enhertu Trial
September 17 2021 - 12:05PM
Dow Jones News
By Chris Wack
AstraZeneca and Daiichi Sankyo Co. said they said the saw
positive results from a Phase II trial that showed Enhertu provided
a clinically meaningful and durable tumor response in patients with
HER2-positive metastatic and/or unresectable gastric or
gastroesophageal junction adenocarcinoma previously treated with a
trastuzumab-containing regimen.
Enhertu fam-trastuzumab deruxtecan-nxki is an HER2-directed
antibody drug conjugate intended to treat gastric cancer.
In the primary analysis, the first trial of Enhertu specifically
in Western patients with HER2-positive metastatic gastric cancer or
GEJ adenocarcinoma, Enhertu demonstrated a confirmed overall
response rate of 38% as assessed by independent central review.
Three complete responses and 27 partial responses were observed
in patients treated with Enhertu. These results were consistent
with those from a previous registrational Phase II trial.
After a median follow-up of 5.7 months, the median duration of
response of Enhertu was 8.1 months. The median progression-free
survival was 5.5 months. An exploratory endpoint of confirmed
disease control rate of 81% was seen.
Enhertu is approved in Israel, Japan and the U.S. for the
treatment of adult patients with locally advanced or metastatic
HER2-positive gastric or GEJ adenocarcinoma who have received a
prior trastuzumab-based regimen based on the results from the
trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 17, 2021 12:50 ET (16:50 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daiichi Sankyo (PK) (USOTC:DSNKY)
Historical Stock Chart
From Sep 2023 to Sep 2024